| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/27/2023 | 20.05% | Stephens & Co. | $420 → $390 | Maintains | Overweight |
| 08/30/2023 | 35.45% | Keybanc | $415 → $440 | Maintains | Overweight |
| 08/21/2023 | 27.75% | Keybanc | $385 → $415 | Maintains | Overweight |
| 07/28/2023 | 18.51% | Keybanc | $375 → $385 | Maintains | Overweight |
| 07/17/2023 | 29.29% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
| 06/16/2023 | 24.67% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
| 04/11/2023 | 23.13% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
| 02/17/2023 | 15.44% | Keybanc | $315 → $375 | Maintains | Overweight |
| 12/14/2022 | -23.04% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
| 12/02/2022 | -3.03% | Keybanc | $350 → $315 | Maintains | Overweight |
| 11/30/2022 | -23.04% | UBS | → $250 | Initiates Coverage On | → Neutral |
| 10/28/2022 | -23.04% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
| 10/28/2022 | 7.74% | Keybanc | $400 → $350 | Maintains | Overweight |
| 07/29/2022 | 6.2% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
| 04/29/2022 | 26.21% | B of A Securities | $475 → $410 | Maintains | Buy |
| 04/29/2022 | 23.13% | Keybanc | $475 → $400 | Maintains | Overweight |
| 09/15/2021 | 58.53% | B of A Securities | $450 → $515 | Maintains | Buy |
| 07/30/2021 | 23.13% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
| 07/30/2021 | 46.22% | Keybanc | $350 → $475 | Maintains | Overweight |
| 04/30/2021 | 4.66% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
| 02/19/2021 | -3.03% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
| 11/10/2020 | 7.74% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
| 10/14/2020 | -7.65% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
| 04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
What is the target price for West Pharmaceutical Servs (WST)?
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Stephens & Co. on October 27, 2023. The analyst firm set a price target for $390.00 expecting WST to rise to within 12 months (a possible 20.05% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Stephens & Co., and West Pharmaceutical Servs maintained their overweight rating.
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on October 27, 2023 so you should expect the next rating to be made available sometime around October 27, 2024.
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $420.00 to $390.00. The current price West Pharmaceutical Servs (WST) is trading at is $324.86, which is out of the analyst's predicted range.